- Skin microbiome plays a crucial role in maintaining and restoring healthy human skin
- Azitra targets skin “friendly” bacteria to solve the challenges of adverse skin conditions and diseases
- Bayer to develop new natural skin care products based on suited skin microbiome bacteria
LEVERKUSEN, Germany & FARMINGTON, Conn.–(BUSINESS WIRE)–Bayer and Azitra Inc., a clinical-stage medical dermatology biotech company, today announced a joint development agreement to collaborate in the identification and characterization of skin microbiome bacteria. The partnership will leverage Azitra’s proprietary panel of Staphylococcus epidermidis strains to identify potential candidates for the treatment of adverse skin conditions and diseases. Based on the results of the research partnership, Bayer plans to develop selected Staphylococcus epidermidis strains into new natural skin care products under a future License Agreement. Prospective areas of application include medicated skin care products for sensitive, eczema-prone skin as well as therapeutic products for skin diseases such as atopic dermatitis.
Recent scientific publications suggest that microorganisms such as bacteria and especially skin-friendly bacteria, commonly referred to as skin microbiome, can significantly contribute to the protection of the skin from hostile invasions. Additional positive effects include supporting the recovery from skin diseases such as atopic dermatitis, acne, and rosacea, and may also accelerate wound healing.
“The skin microbiome offers a promising platform for the development and commercialization of natural skin care products more and more people are looking for. As Bayer is committed to the development of science-based consumer health products through our own research as well as external partnerships, we’re delighted to collaborate with Azitra. The company has already demonstrated tolerability of a selected Staphylococcus epidermidis strain in healthy volunteers and is now planning to start the clinical demonstration of efficacy,” Heiko Schipper, Member of the Board of Management of Bayer AG and President of Bayer Consumer Health, comments on the new partnership.
Bayer, a global leader in innovative and trusted skincare solutions, will actively contribute to the research collaboration by providing suitable topical formulations that are able to maintain Staphylococcus epidermidis viability while showing excellent skin compatibility and sensorial performance.
“We are strongly committed to the potential of the microbiome to provide significant benefits for improved skin health and appearance and by working together with Bayer I am confident we can deliver on the promise of this technology,” states Richard Andrews, President and CEO of Azitra.
Azitra’s versatile platform technology offers further screening options for beneficial strains appropriate for the treatment of dermatological diseases such as atopic dermatitis, acne or psoriasis. In addition, Bayer will review the use of Azitra’s genetically modified bacteria in Dermatology and other Consumer Health areas such as Nutritionals and Digestive Health.
Azitra, Inc. is a clinical-stage medical dermatology company that combines the power of the microbiome with cutting-edge genetic engineering to treat skin disease. The company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its pharmaceutical programs to treat cancer therapy associated skin rashes, targeted orphan indications and atopic dermatitis.
Learn more at www.azitrainc.com
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Dr. Christina Bussfeld, phone +41 58 272 60 97
Michelle Linn, Tel. +1 774 696 3803
Find more information at www.bayer.com.